Alzamend Neuro, Inc. (ALZN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Atlanta, GA, United States. The current CEO is Stephan Jackman.
ALZN has IPO date of 2021-06-15, 4 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $3.2M.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
